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Abstract: Glioblastomas commonly (40%) exhibit epidermal growth factor receptor (EGFR) amplifica-
tion; half of these tumors carry the EGFRvIII deletion variant characterized by an in-frame deletion of
exons 2-7, resulting in constitutive EGFR activation. Although EGFR tyrosine kinase inhibitors had
only modest effects in glioblastoma, novel therapeutic agents targeting amplified EGFR or EGFRvIII
continue to be developed.Depatuxizumab mafodotin (ABT-414) is an EGFR-targeting antibody-drug
conjugate consisting of the mAb 806 and a toxic payload, monomethyl auristatin F. Because glioma cell
lines and patient-derived glioma-initiating cell models expressed too little EGFR in vitro to be ABT-414-
sensitive, we generated glioma sublines overexpressing EGFR or EGFRvIII to explore determinants of
ABT-414-induced cell death.Overexpression of EGFRvIII induces sensitization to ABT-414 more readily
than overexpression of EGFR in vitro and in vivo Exposure to ABT-414 in vivo eliminated EGFRvIII-
expressing tumor cells, and recurrent tumors were devoid of EGFRvIII expression. There is no bystander
killing of cells devoid of EGFR expression. Surprisingly, either exposure to EGF or to EGFR tyrosin
kinase inhibitors reduce EGFR protein levels and are thus not strategies to promote ABT-414-induced
cell killing. Furthermore, glioma cells overexpressing kinase-dead EGFR or EGFRvIII retain binding of
mAb 806 and sensitivity to ABT-414, allowing to dissociate EGFR phosphorylation from the emergence
of the ”active” EGFR conformation required for ABT-414 binding.The combination of EGFR-targeting
antibody-drug conjugates with EGFR tyrosine kinase inhibitors carries a high risk of failure. Promoting
EGFR expression rather than phosphorylation should result in glioblastoma cell sensitization to ABT-414.
DOI: https://doi.org/10.1158/1535-7163.MCT-19-0609





von Achenbach, Caroline; Silginer, Manuela; Blot, Vincent; Weiss, William A; Weller, Michael (2020).
Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression,




Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR 1 
overexpression, but not EGFR
Y1068








, William A. Weiss
3






Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and 7 
University of Zurich, Zurich, Switzerland 8 
2
Abbvie Inc., North Chicago, IL 9 
3
Departments of Neurology, Pediatrics, Neurosurgery, Brain Tumor Research Center, and Helen Diller 10 
Family Comprehensive Cancer Center, University of California, San Francisco, CA 11 
 12 
Corresponding author: Michael Weller, MD, Laboratory of Molecular Neuro-Oncology, 13 
Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, 14 
Switzerland, Tel.: +41 44 255 5500, E-mail: michael.weller@usz.ch 15 
 16 
Running title: EGFR targeting in glioblastoma 17 
 18 
Funding: This study was supported by an unrestricted grant from Abbvie. 19 
 20 
Acknowledgement: The authors thank J. Friesen, F. Wiget and R. Epple for expert technical 21 




Conflict of Interest 24 
CvA and MS report no conflicts of interest. 25 
VB is an employee of Abbvie. 26 
WAW is co-founder of StemSynergy Therapeutics, Inc. 27 
MW has received research grants from Abbvie, Adastra, Bayer, Merck, Sharp & Dohme (MSD), 28 
Merck (EMD), Novocure, Piqur, and Roche, and honoraria for lectures or advisory board 29 
participation or consulting from Abbvie, BMS, Celgene, Celldex, Merck, Sharp & Dohme 30 









Glioblastomas commonly (40%) exhibit epidermal growth factor receptor (EGFR) amplification; 38 
half of these tumors carry the EGFRvIII deletion variant characterized by an in-frame deletion of 39 
exons 2-7, resulting in constitutive EGFR activation. Although EGFR tyrosine kinase inhibitors 40 
had only modest effects in glioblastoma, novel therapeutic agents targeting amplified EGFR or 41 
EGFRvIII continue to be developed. 42 
Depatuxizumab mafodotin (ABT-414) is an EGFR-targeting antibody drug conjugate consisting 43 
of the monoclonal antibody 806 and a toxic payload, monomethyl auristatin F. Since glioma cell 44 
lines and patient-derived glioma-initiating cell models expressed too little EGFR in vitro to be 45 
ABT-414-sensitive, we generated glioma sublines overexpressing EGFR or EGFRvIII to explore 46 
determinants of ABT-414-induced cell death. 47 
Overexpression of EGFRvIII induces sensitization to ABT-414 more readily than overexpression 48 
of EGFR in vitro and in vivo. Exposure to ABT-414 in vivo eliminated EGFRvIII-expressing 49 
tumor cells, and recurrent tumors were devoid of EGFRvIII expression. There is no bystander 50 
killing of cells devoid of EGFR expression. Surprisingly, either exposure to EGF or to EGFR 51 
tyrosin kinase inhibitors reduce EGFR protein levels and are thus not strategies to promote ABT-52 
414-induced cell killing. Furthermore, glioma cells overexpressing kinase-dead EGFR or 53 
EGFRvIII retain binding of mAb 806 and sensitivity to ABT-414, allowing to dissociate EGFR 54 
phosphorylation from the emergence of the “active” EGFR conformation required for ABT-414 55 
binding. 56 
The combination of EGFR-targeting antibody drug conjugates with EGFR tyrosine kinase 57 
inhibitors carries a high risk of failure. Promoting EGFR expression rather than phosphorylation 58 

















Glioblastoma is an invariably fatal brain tumor. Median survival is in the range of 12-15 months. 72 
The current standard of care includes surgery, radiotherapy and chemotherapy using concomitant 73 
and maintenance temozolomide (TMZ/RTTMZ) (1). Accordingly, glioblastoma remains a 74 
disease area of high unmet clinical need. 75 
 Glioblastomas commonly (40%) exhibit amplification of the epidermal growth factor 76 
receptor (EGFR) gene. Half of these tumors carry a deletion mutation of exons 2-7 referred to as 77 
delta-EGFR or EGFRvIII which results in constitutive pathway activity. Multiple oncogenic 78 
properties of glioblastoma have been attributed to strong EGFR signalling, including migration, 79 
invasiveness, and resistance to apoptosis. Various therapeutic agents targeting amplified EGFR 80 
or EGFRvIII are currently being developed. Tyrosine kinase inhibitors (TKI) or monoclonal 81 
antibodies have failed to show benefit in clinical studies, typically in glioblastoma patient 82 
populations unselected for molecular marker profiles (2).  83 
Antibody drug conjugates (ADC) have recently emerged as new promising therapeutic agents in 84 
oncology. They are composed of monoclonal antibodies to cell surface antigens which are 85 
connected to a cytotoxic agent, referred to as the toxic payload, via chemical linkers. Challenges 86 
of developing ADC are finding (i) the ideal antigens with high expression across the tumor, but 87 
with absent or low normal tissue expression, (ii) the ideal linker which prevents the release of the 88 
cytotoxic agent before targeting the antigen in order to prevent off-target effects, and (iii) potent 89 
on-target cytotoxic activity (3-5). Depatuxizumab mafodotin (ABT-414) (6) is an EGFR-90 
targeting antibody drug conjugate consisting of the monoclonal antibody 806 (7) linked through 91 
a non-cleavable linker to a toxic payload, monomethyl auristatin F (MMAF) (8). The 92 
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extracellular domain of EGFR is composed of two cysteine-poor homologous large domains and 93 
two cysteine-rich domains. The epitope recognized by ABT-806 is located on the first cysteine-94 
rich domain of the EGFR extracellular domain. This epitope is masked in the inactive tethered 95 
monomer state (tethered) or in the active ligand-bound “back-to-back” dimer state. Epitope 96 
exposure may occur as a result of extracellular domain truncation, as in EGFRvIII, or with 97 
overexpression of EGFR (6), (7). 98 
MMAF binds to tubulins, disrupts microtubule dynamics and subsequently induces G2/M arrest 99 
and cell death (9-13). ABT-414 exhibits potent cytotoxic activity against glioblastoma patient-100 
derived xenograft models expressing high levels of either wildtype EGFR or EGFRvIII (6). After 101 
early clinical trials in patients with recurrent in newly glioblastoma established ABT-414 safety 102 
and showed signs of drug activity (14), (15),(16), randomized clinicial trials have been 103 
conducted in recurrent (EORTC 1410, NCT02343406) and newly diagnosed (RTOG 3508, 104 
NCT02573324) glioblastoma. 105 
 ABT-806 targets a unique tumor-specific epitope of EGFR which is accessible when 106 
wildtype EGFR is amplified and always when EGFRvIII is expressed. The minimal reactivity 107 
with EGFR expressed in normal tissue made ABT-806 suitable to generate an ADC (7). ABT-108 
414 bound to EGFR is internalized and processed within endosomes and lysosomes to release its 109 
lethal cargo. Yet, several questions regarding the precise mode of action of ABT-414 and 110 
potential pathways of constitutive or acquired resistance to ABT-414 among glioma cells remain 111 
unanswered. Here, we addressed some of them.  112 
 113 
 114 
  115 
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Materials and Methods 116 
 117 
Reagents 118 
Depatuxizumab mafodotin (ABT-414), mAb 806 and Ab095–vcMMAF (control ADC) were 119 
provided by AbbVie Inc. (Chicago, IL). The sequence of Depatuxizumab mafodotin is publicly 120 
available through the WHO INN publication online 121 
(https://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf?ua=1). AB095 122 
is an anti-tetanus toxin IgG1, which does not recognize any epitopes in mice and is therefore an 123 
appropriate isotype control. Gefitinib was obtained from InvivoGen (tlrl-gef; San Diego, CA), 124 
EGF was from PeproTech (Rocky Hill, NJ) and erlotinib from Selleckchem (Houston, TX). 125 




RT-PCR was performed using the 2^(- delta CT) method (17). cDNA was produced by reverse 130 
transcription from total mRNA, applying the “High Capacity cDNA Reverse Transcription Kit” 131 
(Applied Biosystems by Thermo Fisher Scientific, Waltham, MA) and specific target gene 132 
expression, normalized to hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1), was 133 
determined using PowerUpTM SYBR Green Master Mix A25741 (Applied Biosystems by 134 
Thermo Fisher Scientific) and measured by the QuantStudio™ 6 real-time PCR system and 135 
QuantStudio software V1.2 (Thermo Fisher Scientific). Primer sequences were EGFR (forward 136 
5’-GAGTCGGGCTCTGGAGGAAA-3’, reverse 5’-CAGTTATTGAACATCCTCTGG AC-3’) 137 
(18,19); EGFRvIII (forward 5’- GGCTCT GGAGGAAAAG AAAGGTAAT -3’, reverse 5’- 138 
8 
 
CGACAG CTATGAGATGGAGGA -3’) (20). 139 
 140 
Immunoblot analysis 141 
Immunoblot analysis and the nuclear/cytoplasmic sub-fractionation assay was performed as 142 
described (21). Antibodies were rabbit anti-phospho-EGFR (Tyr 1068) and anti-EGFR (1/1000, 143 
Cell Signaling Technology, CST, Danvers, MA), the signals of which were normalized to 144 
GAPDH (1/1000, EB07069, Everest Biotech Ltd, Bicester, UK) or to rabbit anti-lamin B1 145 
(1/2000, Ab 16048, RRID:AB_443298, Abcam, Cambridge, UK) loading controls. HRP-146 
conjugated secondary anti-rabbit antibody (1/5000, #7074, CST) was used as for detection. 147 
 148 
Viability assays and flow cytometry 149 
5’000-30’000 (5’000-15’000 for long-term glioma cell lines (LTC), 15’000-30’000 for glioma-150 
initating cell (GIC) lines) for acute 72 h growth inhibition assays or 50-300 (50-100 for LTC, 151 
100-300 for GIC) cells for clonogenicity or spherogenicity assays were seeded in their respective 152 
medium in 100 µl for LTC or 50 µL for GIC in a 96-well format 24 h prior to ABT-414 153 
treatment at day 0. Cells were treated at day 1 either by replacement of the medium (100 µl + 1x 154 
drug concentration) for LTC or by adding medium (50 µl + 2x drug concentration) for GIC. The 155 
clonogenicity or spherogenicity assays were stopped when the first conditions reached 156 
approximately 80-90% confluency for adherent LTC cultures respectively 80% coverage of the 157 
culture dish area by spheres for GIC. Metabolic activity was assessed by 3-(4, 5-158 
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) reduction either after 72 h for 159 
acute effects or after at least 10 days as a surrogate for colony formation (22). Senescence 160 
staining was performed using the Senescence β-galactosidase Staining Kit (Cell Signalling 161 
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Technology) (23). Details on flow cytometry are provided in Supplementary Note S2. 162 
 163 
Animal studies 164 
All animal experiments were conducted using standard operating procedures under a valid 165 
licence (ZH236/14) granted by the Cantonal Veterinary Office Zurich and Federal Food Safety 166 
and Veterinary Office. Immunocompromised CD1 nude mice (Charles River Laboratories, 167 
Sulzfeld, Germany) were xenografted with 75’000 LN-229 EGFRvIII cells. Stereotactic 168 
intracranial implantation was performed as previously described (23). Ten days post surgery 169 
mice were treated every 4 days for a total of six doses by intraperitoneal administration with 170 
ABT-414 or Ab095–vcMMAF (isotype control ADC) (10 mg/kg). Mice were assessed for 171 
neurological symptoms daily according to the Cantonal Veterinary Office Zurich guidelines. 172 
Three animals per treatment group and four animals per control groups were pre-randomized and 173 
euthanized when the first mouse became symptomatic. For survival analysis seven to eight 174 
animals per group were euthanized when developing neurological symptoms.  175 
 176 
Histology and immunohistochemistry 177 
Brains sections (8 μm) were fixed with paraformaldehyde, pretreated with 3% H2O2 and blocked 178 
with blocking solution (Biosystems, Muttenz, Switzerland). Sections were immunostained with a 179 
rabbit polyclonal antiserum (lot #111611, Celldex) that binds the EGFRvIII protein (antibody 180 
dilution: 1:2000). SignalStain
®
 Boost IHC Detection Reagent (HRP, Rabbit) (#8114)  (CST) and 181 
the ImmPact DAB kit (#SK-4105, Vector Laboratories, Burlingame, CA) were used to visualize 182 




Statistical analysis 185 
Representative data of experiments, performed in technical and usually three biological 186 
replicates, are shown here and are presented as mean values and standard deviations. One-way as 187 
well as two-way ANOVA with Bonferroni post-hoc testing (multiple comparisons) were used for 188 
statistical analyses. Antagonistic effects were calculated by the fractional product method (24) 189 
and differences of >10% of the observed versus predicted (
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴 ×𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐵100 ) reduction of 190 
viability were considered as indicative of synergy or antagonism. 191 





Generation and characterization of EGFR and EGFRvIII glioma models 195 
We have recently characterized a panel of human LTC and GIC for the expression and activity of 196 
EGFR and their sensitivity to the EGFR tyrosine kinase inhibitor, gefinitib (21). These cell lines 197 
were uniformly refractory to ABT-414 at concentrations of up to 10 nM for exposure times of up to 198 
72 h (Fig. S1A). Therefore, we obtained stable transfected sub-cell lines of two LTC (U87MG, LN-199 
229) and one GIC (S-24) overexpressing wildtype EGFR, referred to herein as EGFR or EGFRvIII 200 
(Fig. 1A). Immunoblot demonstrated that overexpression of EGFR or EGFRvIII resulted in 201 
enhanced EGFR or EGFRvIII phosphorylation (Fig. 1B). Cell surface staining for wildtype EGFR 202 
or EGFRvIII resulted in increased specific fluorescence indexes (SFI) for EGFR↑ cells using an 203 
anti-EGFR wildtype specific antibody and for EGFRvIII-expressing cells using an anti-EGFRvIII 204 
specific antibody (Fig. 1C). Exposure to exogenous EGF increased pEGFR levels strongly in 205 
EGFR cells, more so in U87MG and LN-229 than in S-24 cells. EGFRvIII is known not to bind 206 
EGF. Yet, in EGFRvIII-transfected LN-229 and S-24 cells, EGF induced pEGFR to higher levels 207 
than in control-transfected cells, indicating that the co-expression of EGFRvIII facilitates 208 
phosphorylation of EGFR in response to EGF (Fig. 1D, Fig. S2A). Removal of EGF from the 209 
culture medium for 48 h decreased pEGFR remarkably in EGFR cells, but also to a lesser extent in 210 
EGFRvIII cells, further substantiating a role of endogenous EGFR mediating EGFRvIII 211 
phosphorylation in response to EGF (Fig. 1E, Fig. S2B). EGFRvIII cells showed a significant 212 
growth advantage over control or EGFR cells for all three models. U87MG EGFR cell 213 
proliferation was enhanced over control, too (Fig. 1F). Since EGF is an essential component of the 214 
medium used to maintain GIC cultures, we next explored whether ectopic EGFR or EGFRvIII 215 
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expression rendered the cells less dependent on EGF for survival and sphere formation. Indeed, 216 
removal of EGF from the culture medium resulted in growth inhibition of S-24 control and EGFR 217 
cells whereas S-24 EGFRvIII cells required no external EGF for growth (Fig. S3A,B). 218 
 219 
Ectopic EGFR expression confers glioma cell sensitivity to ABT-414 in vitro 220 
EGFR phosphorylation was largely refractory to ABT-414 exposure at 24 h in EGFR cells 221 
whereas phosphorylation was reduced by ABT-414 in all EGFRvIII cell lines. Total EGFR was 222 
unaffected in EGFR cells; total transfected EGFRvIII was unaffected in U87MG and S-24, but 223 
moderately reduced in LN-229 cells (Fig. 2A, Fig. S2C). In 72 h exposure assays, expression of 224 
EGFRvIII induced sensitivity to ABT-414 in all three models examined, U87MG, LN-229 and S-225 
24, whereas overexpression of wildtype EGFR induced moderate sensitization in U87MG and LN-226 
229 only; Of note, S-24 may be less sensitive to ABT-414 in these short-term assays because of 227 
slower proliferation rate compared to U87MG or LN-229 (Fig. 2B). There was thus correlation 228 
between early effects on pEGFR levels and effects on growth 48 h later. The specificity of killing 229 
was verified by the demonstration of rescue of cell death by unarmed ABT-806 antibody (Fig. 230 
S1B). Next, we investigated the effect of ABT-414 treatment on clonogenicity (LTC) or 231 
spherogenicity (GIC). Growth of EGFRvIII cells was again strongly inhibited even by low 232 
concentrations of ABT-414. Overexpression of wildtype EGFR induced sensitivity to ABT-414 in 233 
these assays, too, in all cell lines (Fig. 2C, Table S1). The cytotoxic agent MMAF is known to 234 
inhibit the polymerization of tubulin as well as destabilizing microtubule structures once inside the 235 
cell causing cell cycle arrest in G2/M (25). Since we observed that, in the duration of  the assay, 236 
ABT-414 prevented proliferation to a greater extent than causing acute cytotoxicity, in particular in 237 
EGFR cells, we performed cell cycle analysis. Treatment with ABT-414 for 72 h induced a minor 238 
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G2/M arrest in EGFRvIII cells with a fold difference of 1.8 for LN-229 and S-24 cells, but no such 239 
effect in EGFR LN-229 cells and S-24 cells. There was also relative increase in sub-G1, which 240 
represents the dead or dying cell fraction, in both EGFR and EGFRvIII cells (Fig. 2D). Altogether, 241 
these data suggest that cell death induced by ABT-414 is delayed and underestimated when 242 
assessed at 72 h (Fig. 2B,C). -galactosidase staining indicated that induced senescence may 243 
mediate some of the delayed effects of ABT-414 in LN-229 EGFR and EGFRvIII sub-cell lines 244 
(Fig. 2E), although no such effects were seen in S-24 (Fig. S4). 245 
 246 
ABT-414 prolongs survival in an EGFRvIII overexpressing orthotopic mouse glioma model 247 
The efficacy of ABT-414 in vivo was assessed in the three LN-229 human orthotopic xenograft 248 
models in nude mice. A comparison of PBS-treated controls showed that the expression of wild-249 
type EGFR and, even more prominently, of EGFRvIII in tumors decreased animal survival (Fig. 3). 250 
There was no difference between Ab095-vcMMAF and PBS treatment in either model, whereas 251 
ABT-414 specifically and profoundly prolonged survival of mice carrying EGFRvIII-expressing 252 
tumors (Mantel-Cox test). ABT-414 did not prolong survival in mice carrying tumors generated by 253 
control-transfected cells or wild-type EGFR-overexpressing cells however (Figure 3A,C,E). 254 
Immunohistochemistry for EGFRvIII confirmed EGFRvIII expression in EGFRvIII-transfected 255 
cells, and demonstrated loss of expression in tumors from mice treated with ABT-414 but not with 256 
control PBS or Ab095-vcMMAF (Fig. 3F, Fig. S5). When tumors from mice treated with Ab095-257 
vcMMAF or ABT-414 were harvested from end-stage animals several weeks after conclusion of 258 
therapy, loss of EGFRvIII had persisted in ABT-414-treated animals (Fig. S6A). Furthermore, 259 




Synergy of ABT-414 with irradiation or alkylating agents in vitro 262 
With a view on the clinical application of ABT-414, we also asked whether ABT-414 activity was 263 
negatively or positively affected by hypoxia, a typical feature of glioblastoma, or co-exposure to 264 
irradiation or two alkylating agents commonly used in this disease setting, TMZ and lomustine. The 265 
sensitivity of EGFR cells to ABT-414 was essentially unaltered under hypoxia whereas EGFRvIII 266 
cells were moderately more resistant under hypoxic conditions (Fig. S7). Then we tested whether 267 
lomustine, TMZ or irradiation may induce upregulation of EGFR expression and its activation, 268 
which might enhance ABT-414 binding activity. However, only minor pEGFR induction was 269 
observed. Longer exposure revealed either similar results or no alteration of pEGFR levels at all 270 
(Fig. S8A,C). Co-exposure to ABT-414 and lomustine, TMZ or irradiation resulted in largely 271 
additive, rarely synergistic, but never antagonistic effects (Fig. S8B,D). 272 
 273 
No bystander effect of ABT-414 274 
Next, we explored whether cytotoxic effects of ABT-414 are strictly limited to cells overexpressing 275 
EGFR, or whether there could also be some level of bystander killing, e.g., from free toxin 276 
circulating from cell to cell. 277 
 We co-cultured EGFRvIII LN-229 or ZH-161 cells with LN-229 or ZH-161 cells expressing 278 
GFP only and treated these mixed cultures with ABT-414. In these studies, cell death induction was 279 
restricted to non-GFP-expressing cells, excluding any relevant bystander effect in vitro (Fig. 4).  280 
 281 
Ligand stimulation limits rather than promotes ABT-414 activity 282 
Since ABT-414 is supposed to recognize a specific activation-related conformation of EGFR (6), 283 
we also explored whether co-exposure to EGF concentrations sufficient to induce pEGFR sensitized 284 
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cells to ABT-414 by promoting the “active” EGFR conformation. This was not the case (Fig. S9A). 285 
Flow cytometry demonstrated that pre-stimulation of cells with EGF for 15 min rather decreased 286 
cellular reactivity with mAb 806, the antibody moiety of ABT-414, more so in LN-229 than in S-24 287 
cells (Fig. S9B,C). In agreement, pre- or post-stimulation with EGF relative to ABT-414 treatment 288 
conferred minor antagonism particularly in U87MG control and EGFR cells, in LN-229 EGFR 289 
and EGFRvIII cells and in S-24 EGFRvIII cells, and EGF stimulation alone increased proliferation 290 
in some models (Fig. S9D,E). The antagonistic effects of EGF in the EGFRvIII models once more 291 
suggest a role for endogenous EGFR in regulating overall signaling activity. In summary, no 292 
synergy was observed by combining EGF-induced EGFR phosphorylation and ABT-414 treatment. 293 
On the contrary, slight antagonism was detected, suggestive of EGF-mediated receptor 294 
internalization, leading to lower EGFR density at the cell surface and relative resistance to ABT-295 
414, as well as enhanced proliferation. 296 
 297 
EGFR TKI limit rather than promote ABT-414 activity 298 
Given these data, we wondered whether inhibiting rather than activating the EGFR pathway might 299 
increase EGFR availability for ABT-414 binding at the cell surface. However, when the glioma 300 
cells were exposed to gefitinib at concentrations sufficient to inhibit EGFR phosphorylation (21), 301 
there was strong reduction of mAb 806 binding, suggesting that EGFR dephosphorylation decreases 302 
ability of ABT-414 binding (Fig. 5A). However, flow cytometry using an EGFR antibody that 303 
recognizes both EGFR wildtype and EGFRvIII, revealed decreased labeling too (Fig. 5B), 304 
suggesting loss of EGFR protein from the cell surface upon gefitinib treatment. Gefitinib treatment 305 
induced decreased pEGFR levels as well, and led to a strong decrease of total EGFR wildtype and 306 
EGFRvIII protein as detected by immunoblots of total cellular lysates (Fig. 5C). This effect was not 307 
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specific to gefitinib since erlotinib had similar effects in S-24 cells and, was not restricted to glioma 308 
cells since A431 cells showed the same response to erlotinib (Fig. S10A,B). 309 
Next, we asked whether the combination of ABT-414 with gefitinib would also result in 310 
antagonism, given that gefitinib at certain concentrations reduces expression of the target of ABT-311 
414. Indeed, co-exposure to ABT-414 and gefitinib revealed antagonism in LN-229 EGFR and 312 
EGFRvIII, as well as in S-24 EGFRvIII cells (Fig. 5D). 313 
 314 
EGFR phosphorylation is dispensable for ABT-414 activity 315 
To further test the premise of decreased mAb-806 binding activity upon receptor deactivation, 316 
experiments using kinase-dead EGFR and EGFRvIII cells (26) were performed. EGFR 317 
phosphorylation was reduced or lost in kinase-dead EGFR or EGFRvIII cells, and stimulation with 318 
EGF only moderately induced phosphorylation compared to the strong effect in kinase-active cells 319 
(Fig. 6A, Fig.S2D). In order to further explore the loss of EGFR protein and the relevance of EGFR 320 
phosphorylation for its effective targeting, we performed flow cytometry and immunoblot with an 321 
antibody targeting wildtype EGFR and EGFRvIII. Stimulation with EGF decreased antibody 322 
binding in EGFR and EGFRvIII, but not in kinase-dead cells. Furthermore, phosphorylation 323 
increased upon EGF stimulation in kinase-active, but not in kinase-dead cells. However, both in 324 
kinase-active as well as in kinase-dead cells, treatment with gefitinib more than with ABT-414 325 
decreased EGFR on the cell surface, measured by flow cytometry and immunoblot (Fig. 6B,C). 326 
Finally, sensitivity to ABT-414 was invariable in both kinase-dead cells as well as in kinase-active 327 





ABT-414, a novel ADC targeting EGFR, has shown promising clinical activity in patients with 331 
EGFR-amplified recurrent glioblastoma (15,27,28). However, among these patients, it has remained 332 
challenging to identify which patients respond and which do not, and a significant fraction of 333 
patients appears not to respond, despite high level EGFR amplification. 334 
 Since ABT-414-mediated cell killing correlates with EGFR density at the cell surface in vitro 335 
(6), we first sought to correlate EGFR and EGFRvIII expression with the cytotoxic activity of ABT-336 
414 in 9 LTC and 5 GIC glioma models. The uniform resistance of these glioma cell lines to ABT-337 
414 was somewhat surprising since some of these cell lines exhibit robust EGFR expression (Fig. 338 
S1A) (21). Phillips et al. (2016) reported that ABT-414 displayed cytotoxic effects in A431, an 339 
EGFR wildtype amplified vulvar epidermoid carcinoma cell line and in HCC827.ER.LMC, an 340 
EGFR wildtype amplified lung adenocarcinoma cell line only, with EC50 values ≤ 10 nM. 341 
Concentration response studies in our study revealed that 10 nM was the highest applicable, non-342 
toxic dose for the MMAF control ADC. The EC50 values of other EGFR wildtype amplified cell 343 
lines tested by Phillips et al. (2016) were above 10 nM. Constitutive cancer cell line sensitivity to 344 
ABT-414 in vitro thus seems to be rare. 345 
 EGFR amplification and expression of EGFRvIII mutation are lost in vitro upon culturing of 346 
primary glioma cells (29,30). Thus, we generated stable transfected sub-cell lines, designed to either 347 
overexpress EGFR wildtype (EGFR) or EGFRvIII (Fig. 1). In our model systems, early loss of 348 
phosphorylated EGFRvIII correlated best with the activity of ABT-414 (Fig. 2A, Fig. S2C). 349 
Overexpression of EGFRvIII in cell lines resulted in robust ABT-414-mediated cytotoxicity 350 
whereas overexpression of wildtype EGFR had a lesser effect (Fig. 2B). ABT-414 had more 351 
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prominent effects in clonogenicity than in acute cytotoxicity assays with EC50 values ranging from 352 
2.1-8.43 nM versus > 10 nM in EGFRcells and 7.8 x 10-5-0.03 nM versus 0.41-6 nM in EGFRvIII 353 
cells (Fig. 2B,C, Table S1). Cell cycle analyses after 72 hours exposure did not reveal specific 354 
changes induced by ABT-414, suggesting that G2/M arrest-independent, delayed cell death is likely 355 
the best explanation for more prominent effect of ABT-414 with prolonged exposure. In addition, 356 
the toxic payload may induce features of senescence in some cell lines (Fig. 2E). Strong anti-glioma 357 
activity of ABT-414 was confirmed in vivo in the orthotopic LN-229 EGFRvIII glioma xenograft 358 
model. EGFRvIII expression was virtually lost in tumors of mice that had been treated with ABT-359 
414, likely as a consequence of selection of cells with little or no transcription from the plasmid, 360 
demonstrating the long-lasting effect of ABT-414 in vivo as long as the target is expressed, but also 361 
highlighting potential escape pathways from ABT-414 treatment (Fig. 3, S5, S6).  362 
 The EORTC 1410 trial, which evaluated the efficacy of ABT-414 plus TMZ versus ABT-414 363 
alone versus TMZ or lomustine (CCNU) alone (NCT02343406) suggested a trend toward a better 364 
activity for the combination of ABT-414 and TMZ, although the results were not statistically 365 
significant (p>0.05) (31). Combination experiments in vitro with ABT-414 and with lomustine, 366 
TMZ or irradiation showed predominantly additive effects in our model systems in vitro (Fig. S8). 367 
 The activity of ABT-414 is believed to result from internalization of EGFR bound to ABT-414 368 
and subsequent degradation in lysosomal compartments, leading to release of Cys-mc-MMAF 369 
(32,33). Furthermore, it is assumed that MMAF exhibits no cell membrane permeability which 370 
prevents bystander killing (34,35). Co-culture studies indeed confirmed the absence of bystander 371 
killing in our experimental set-ups (Fig. 4). 372 
 Based on the suggested binding properties of ABT-414 (11,12,36), we anticipated that pre- or 373 
co-exposure to exogenous EGF would enhance the binding activity of ABT-414, due to the 374 
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suggested stabilization of the EGFR extended conformation by the ligand (36). This was not the 375 
case. In contrast, EGF stimulation of EGFR wildtype- or vIII-overexpressing cells rather decreased 376 
the reactivity with mAb 806 (Fig. S9A-E). Ligand-induced EGFR dimerization or oligomerization 377 
eventually enhances internalization (37,38), which would prevent mAb 806 binding. In line with 378 
this, pre-exposure of cells to EGF interfered with the activity of ABT-414 (Fig. S9F,G). Similar 379 
results were observed in BaF/3, a murine interleukin-3 dependent pro B cell line. Pre-incubation 380 
with EGF decreased the reactivity with mAb 806, too; however, the authors claimed that this effect 381 
was not due to internalization of the receptor but rather through steric hindrance or masking of the 382 
epitope by the ligand (36). 383 
 MAb 806 is believed to bind to the extended, untethered conformation (active) of EGFR which 384 
occurs as EGFR moves from a tethered conformation (inactive) to an active “back-to-back” dimer 385 
state (11). Preventing activation of EGFR using the tyrosine kinase inhibitor, gefitinib, decreased 386 
mAb 806 activity, but, surprisingly, more likely due to loss of EGFR protein from the cell surface 387 
upon gefitinib treatment than due to a conformational change of EGFR (Fig. 5A-D). 388 
 389 
Furthermore, using LN-229 sub-cell lines expressing kinase-dead EGFR or EGFRvIII, we 390 
demonstrate that phosphorylation of EGFR is dispensable for binding of mAb 806 as well as for the 391 
cytotoxic activity of ABT-414 or gefitinib (Fig. 6A-D). It was previously shown that mutations in 392 
the tyrosine kinase domain do not affect the binding affinity of gefitinib in non-small-cell lung 393 
cancer cells (39). However, the preserved activity of ABT-414 in the kinase-dead models represent 394 
potentially the most important novel finding reported here because these data, albeit in an artificial 395 
model, dissociate EGFR phosphorylation from the “active” conformation thought to be required for 396 
the binding of mAb 806. 397 
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 Accordingly, expression of EGFR at the cell surface rather than EGFR phosphorylation may be 398 
the best predictor of benefit from ABT-414 at the level of the target. Efforts to modulate sensitivity 399 
of tumors to ABT-414 by modulating EGFR levels, through either ligand-dependent stimulation or, 400 
more importantly, pharmacological inhibition using tyrosine kinase inhibitors, should therefore be 401 
explored with caution and may actually be counterproductive.  402 
Our study has limitations. Data were obtained with artificial models engineered to overexpress 403 
wildtype EGFR or EGFRvIII because there was no other option to elucidate modes of action of 404 
ABT-414. We did not explore the kinetics of EGFR internalization with or without EGF or EGFR 405 
inhibitors nor did we explore the down-stream mechanisms of EGFR regulation such as 406 
ubiquitination, although an increasing body of literature suggests a role for ligand-independent 407 
trafficking of EGFR (40,41). Although EGFRvIII rather than EGFR overexpression uniformly 408 
induced glioma cell sensitivity to ABT-414 (Table S1), EGFRvIII expression has not emerged as a 409 
biomarker for benefit from ABT-414 in the clinic (31), potentially challenging the clinical relevance 410 
of our observations. A simple explanation for the higher sensitivity of EGFRvIII cells in vitro 411 
would be their increased growth rate compared with EGFR cells. Pre- and post-ABT-414 exposure 412 
studies in human patients will clarify whether EGFRvIII-expressing are still preferentially 413 
eliminated. Since all EGFRvIII-positive tumors overexpress EGFR wildtype too, preferential 414 
elimination of the fraction of EGFRvIII-expressing cells, which is highly variable in human 415 
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Figure Legends 558 
 559 
Figure 1. Generation and characterization of glioma cells expressing wildtype EGFR or 560 
EGFRvIII. A,B. Characterization of EGFR or EGFRvIII mRNA expression by RT-PCR (A, y-axis 561 
representing mRNA of EGFR or EGFRvIII relative to HPRT1) or protein levels by immunoblot 562 
(wildtype (wt) EGFR: 175 kDa, EGFRvIII: ~140 kDa) (B). C. Cell surface EGFR was assessed by 563 
flow cytometry with anti-EGFR-FITC recognizing EGFR wildtype only (upper rows) or anti-564 
EGFRvIII-PE recognizing specifically EGFRvIII (lower rows). Specific fluorescence indexes (SFI) 565 
were calculated by dividing the mean fluorescence intensity of anti-EGFR-FITC- or anti-EGFRvIII-566 
PE-labelled cells by the mean fluorescence intensity of isotype control-labelled cells and are 567 
included in the right upper corners of each panel. D,E. EGFR phosphorylation without and with 568 
EGF exposure (50 ng/ml, 15 min) (D) or with and without EGF deprivation for 48 h (E) determined 569 
by immunoblot. F. Limiting dilution clonogenicity (LTC) or spherogenicity (GIC) of control (ctr), 570 
EGFR↑ or EGFRvIII cells. GAPDH was used as a loading control for immunoblot. Metabolic 571 
activity was assessed by MTT assay after 10-20 days. Data are expressed as mean ± SEM (*p<0.05, 572 
***p<0.001: EGFR↑ or EGFRvIII versus ctr, two-way ANOVA with Bonferroni correction). 573 
 574 
Figure 2. Ectopic EGFR or EGFRvIII expression induce sensitivity to ABT-414. A. Cells were 575 
exposed to ABT-414 or Ab095–vcMMAF control toxin (10 nM, 24 h) and whole cell lysates were 576 
assessed for phosphorylated and total EGFR by immunoblot (wildtype EGFR: 175 kDa, EGFRvIII: 577 
~140 kDa), using GAPDH as a loading control. B,C. LN-229, U87MG or S-24 control-transfected 578 
(ctr), EGFR↑ or EGFRvIII cells were exposed to ABT-414 or Ab095–vcMMAF control toxin. 579 
Metabolic activity after 72 h (B) or clonogenic survival (C) were assessed by MTT assay (means 580 
and SEM, n=3, *p<0.05, ***p<0.001: ABT-414 versus control toxin, two-way ANOVA with 581 
25 
 
Bonferroni correction). D. LN-229 or S-24 sublines were treated with 10 nM ABT-414 or Ab095–582 
vcMMAF control toxin for 72 h and cell cycle distribution was measured by PI staining. E. LN-229 583 
sub-cell lines were treated with ABT-414 or control antibody for 72 h and subsequently subjected to 584 
-galactosidase staining, using irradiation at 20 Gy as a positive control. 585 
 586 
Figure 3. ABT-414 prolongs survival in the orthotopic EGFRvIII LN-229 glioma model. Mice 587 
were inoculated with LN-229 control (A,B), EGFR↑ (C,D) or EGFRvIII (E,F) cells and treated 588 
every 4 days for a total of six doses with PBS, Ab095–vcMMAF or ABT-414 (8 mg/kg). Survival is 589 
shown by Kaplan-Meier curves (median survival in days provided in brackets) (A,C,E). 590 
Prerandomized animals were euthanized at day 32 and cryosections of the brains were stained with 591 
a polyclonal rabbit anti-EGFRvIII antibody. Representative stainings of mice treated with Ab095–592 
vcMMAF or ABT-414 are depicted (size bar: 100 µm). 593 
 594 
Figure 4. No bystander killing of EGFRvIII-negative glioma cells by ABT-414. LN-229 (A, C) 595 
or ZH-161 (B, D) EGFRvIII- or GFP-transfected cells were exposed to 10 nM ABT-414, either 596 
each cell line alone in a well or both cell lines together in a well, in a co-culture assay for 72 h. Cell 597 
killing was assessed by Zombie-NIR, a cell impermeable dye to label cells with compromised 598 
membranes, and then measured by flow cytometry. Cell populations were divided into GFP-positive 599 
cells, EGFRvIII cells, or both cell lines together and the alive or respective dead cells were 600 
measured for the GFP-positive and the GFP-negative cell population, and the respective cell 601 




Figure 5. Effect of EGFR tyrosine kinase inhibition on mAb 806 binding activity. A,B. LN-229 604 
cells were pretreated for 24 h with gefitinib and then labelled either with mAb-806-PE (A) or with 605 
anti-EGFR-FITC recognizing both wildtype EGFR and EGFRvIII (B). C. Phosphorylated and total 606 
EGFR of gefitinib-treated (24 h) LN-229 sub-cell lines were measured by immunoblot, using 607 
GAPDH as a loading control (left: short exposure, right: long exposure of the same blot). D. LN-608 
229 or S-24 sub-cell lines were pretreated with gefitinib (5 μM) 4 h, then 10 nM ABT-414 for 609 
parental or EGFR cells or 0.1 nM for U87MG and LN-229 EGFRvIII cells or 1 nM for S-24 610 
EGFRvIII was added. Metabolic activity was measured after 72 h by MTT assay and is expressed 611 
normalized to vehicle control (* antagonistic effect defined as difference of >10% of observed 612 
versus predicted effect). 613 
 614 
Figure 6. EGFR phosphorylation is not required for mAb 806 binding and ABT-414 615 
cytotoxicity. A. EGFR or EGFRvIII cell lines without or with the kinase-dead (D813N) mutation 616 
were examined for pEGFR and total EGFR levels by immunoblot. The cells were either pre-617 
stimulated with EGF (50 ng/ml, 15 min) or not. B. The cell lines were either stimulated with EGF 618 
(50 ng/ml, 15 min) or treated with gefitinib (5 µM), using DMSO as control or ABT-414 (10 nM), 619 
using MMAF as control, and levels of EGFR at the cell surface were measured by flow cytometry 620 
with anti-EGFR-FITC recognizing both wildtype EGFR and EGFRvIII (B) or pEGFR and EGFR 621 
were measured in whole cell lysates by immunoblot (C). D. LN-229 EGFR or EGFRvIII cell lines 622 
without or with the kinase-dead (D813N) mutation were exposed to ABT-414 or Ab095–vcMMAF 623 
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